Cargando…
228. Fluoroquinolone Prescribing for Diabetic Foot Infections following an FDA Drug Safety Communication for Aortic Aneurysm Risk
BACKGROUND: Fluoroquinolones were commonly prescribed for hospitalized patients with diabetic foot infection (DFI) at our institution, included in 69% of empiric antibiotic regimens from 2011–2014. On December 20, 2018, the U.S. Food and Drug Administration (FDA) issued a Drug Safety Communication r...
Autores principales: | Li, Catherine, Mercuro, Nicholas J, Chapin, Ryan, Gold, Howard, McCoy, Christopher |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776833/ http://dx.doi.org/10.1093/ofid/ofaa439.272 |
Ejemplares similares
-
54. Microbiologic Characterization and Antibacterial Use in Hospitalized Adults with covid-19 Infection
por: Chapin, Ryan, et al.
Publicado: (2020) -
Diminishing returns, increasing risks: Impact of antibiotic duration of therapy on respiratory bacterial isolates in hospitalized patients during the coronavirus disease 2019 (COVID-19) pandemic
por: Li, Catherine, et al.
Publicado: (2021) -
1863. Antibiotic Prescribing Before and After an FDA Boxed Warning on Fluoroquinolones in 2016
por: Willis, Zachary, et al.
Publicado: (2018) -
1329. Vancomycin Therapeutic Drug Monitoring: How to hit the Curve
por: Vala, Michael, et al.
Publicado: (2020) -
1092. Impact of Relieving Infectious Diseases Fellows from Off-Hour/Weekend Antimicrobial Stewardship Coverage
por: Lee, Matthew S L, et al.
Publicado: (2019)